Reversal of novel oral anticoagulants

Authors

Winnie Lee, Philadelphia College of Osteopathic Medicine
Deepa V. Patel, Philadelphia College of Osteopathic MedicineFollow
Dusty L. Lisi, Philadelphia College of Osteopathic MedicineFollow

Document Type

Article

Publication Date

2015

Abstract

Oral anticoagulants are commonly prescribed for the prevention and treatment of thromboembolic disorders. Coagulopathy is an inherent risk for all anticoagulants, and data regarding reversal of newer agents are sparse. Unlike warfarin, limited options currently exist for rapid reversal of novel oral anticoagulants (direct thrombin inhibitors, factor Xa inhibitors) and include fresh frozen plasma and prothrombin complex concentrates. While no true antidote is yet available, several promising agents are in development. As a result, healthcare providers, principally pharmacists, must be prepared to appropriately monitor and manage patients requiring reversal. © 2000 - 2015 Jobson Medical Information LLC unless otherwise noted.All rights reserved.

Publication Title

U.S.Pharmacist

Volume

40

Issue

2

First Page

HS3

Last Page

HS7

Comments

This article was published in U.S.Pharmacist, Volume 40, Issue 2, Pages HS3-HS7.

Copyright © 2015.

Recommended Citation

Lee, Winnie; Patel, Deepa V.; and Lisi, Dusty L., "Reversal of novel oral anticoagulants" (2015). PCOM Scholarly Papers. 1137.
https://digitalcommons.pcom.edu/scholarly_papers/1137